Literature DB >> 7513227

Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency.

A Gardulf1, H Björvell, R Gustafson, L Hammarström, C I Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7513227

Source DB:  PubMed          Journal:  Immunodeficiency        ISSN： 1067-795X


× No keyword cloud information.
  11 in total

1.  Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.

Authors:  Ann Gardulf; Uwe Nicolay; Oscar Asensio; Ewa Bernatowska; Andreas Böck; Beatriz Costa Carvalho; Carl Granert; Stefan Haag; Dolores Hernández; Peter Kiessling; Jan Kus; Jaune Pons; Tim Niehues; Sigune Schmidt; Ilka Schulze; Michael Borte
Journal:  J Clin Immunol       Date:  2006-04-26       Impact factor: 8.317

Review 2.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors:  Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

3.  Patients' attitude to subcutaneous immunoglobulin substitution as home therapy.

Authors:  J M Kittner; B Grimbacher; W Wulff; B Jäger; R E Schmidt
Journal:  J Clin Immunol       Date:  2006-06-17       Impact factor: 8.317

4.  Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies.

Authors:  R Gustafson; A Gardulf; S Hansen; H Leibl; W Engl; M Lindén; A Müller; L Hammarström
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

5.  Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens.

Authors:  Akhilesh Chouksey; Kimberly Duff; Nancy Wasserbauer; Melvin Berger
Journal:  Allergy Asthma Clin Immunol       Date:  2005-09-15       Impact factor: 3.406

6.  Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.

Authors:  Jennifer Heimall; Junliang Chen; Joseph A Church; Rhonda Griffin; Isaac Melamed; Gary I Kleiner
Journal:  J Clin Immunol       Date:  2016-06-25       Impact factor: 8.317

Review 7.  Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency.

Authors:  Stephen Jolles
Journal:  Immunotargets Ther       Date:  2013-09-18

8.  Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.

Authors:  Lisa Kobrynski
Journal:  Biologics       Date:  2012-08-24

9.  Experience with Subgam, a Subcutaneously Administered Human Normal Immunoglobulin (ClinicalTrials.gov--NCT02247141).

Authors:  Clive Dash; Ernie Gascoigne; Kate Gillanders; Hock Gooi
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

10.  Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".

Authors:  B Bienvenu; G Cozon; C Hoarau; M Pasquet; P Cherin; P Clerson; E Hachulla; J C Crave; J C Delain; R Jaussaud
Journal:  Orphanet J Rare Dis       Date:  2016-06-22       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.